Status:

UNKNOWN

CLaret Embolic Protection ANd TAVI - Trial

Lead Sponsor:

University of Leipzig

Conditions:

Frequency of Cerebral Perfusion Defects After TAVI

Size of Cerebral Perfusion Defects After TAVI

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This prospective, randomized study was designed to investigate the benefit of using a Filter-Protection-Device (Claret MontageTM Dual Filter System) during transcatheter aortic valve implantation (TAV...

Eligibility Criteria

Inclusion

  • Subject must be scheduled to undergo an endovascular aortic valve prosthesis (Medtronic CoreValve®) implant procedure with the femoral artery as the intended access site for the valve delivery system.

Exclusion

  • Patient is unsuitable for TAVI
  • Prior Stroke or TIA in the last 12 month
  • Carotic stenosis \>70%
  • Relevant stenosis of the brachiocephalic trunc or the right subclavian artery
  • Expected Non-compliance for follow-ups
  • Pregnancy
  • Patient is already recruited for another study

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2015

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT01833052

Start Date

April 1 2013

End Date

June 1 2015

Last Update

May 5 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Leipzig Herzzentrum

Leipzig, Germany, 04289

CLaret Embolic Protection ANd TAVI - Trial | DecenTrialz